Connor Clark & Lunn Investment Management Ltd. Boosts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Connor Clark & Lunn Investment Management Ltd. grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 115.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 20,511 shares of the biopharmaceutical company's stock after acquiring an additional 11,008 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in Regeneron Pharmaceuticals were worth $21,562,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of REGN. International Assets Investment Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock valued at $926,078,000 after purchasing an additional 879,916 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock valued at $868,757,000 after buying an additional 184,561 shares in the last quarter. Swedbank AB acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $129,257,000. Epoch Investment Partners Inc. purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $99,667,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company's stock worth $525,804,000 after acquiring an additional 96,266 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Down 0.2 %

Shares of REGN traded down $1.84 during midday trading on Thursday, hitting $741.51. The company had a trading volume of 105,112 shares, compared to its average volume of 533,242. The company's 50-day simple moving average is $961.76 and its 200-day simple moving average is $1,030.14. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market capitalization of $81.48 billion, a P/E ratio of 18.40, a P/E/G ratio of 2.81 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 1 year low of $735.95 and a 1 year high of $1,211.20.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company's stock, valued at $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 7.48% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on REGN shares. BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an "outperform" rating and a $1,150.00 target price for the company. Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, October 22nd. Finally, Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.